Case Report: two cases of idiopathic plasmacytic lymphadenopathy subtype of idiopathic multicentric Castleman disease with xanthelasma palpebrum from a Canadian center

Read full text
Authors: A. Chen, Vivian T. Yin, Paula Blanco, Mark Trinder, Richard I. Crawford, Ryan Henrie, Stephen Parkin, Nasreen Khalil, Mollie N. Carruthers, L Zhang, L. Chen
Cited by: 2
References: 26

Abstract

Background Idiopathic plasmacytic lymphadenopathy is a newly recognized subtype of idiopathic multicentric Castleman disease (iMCD-IPL) and often mimics IgG4-related disease (IgG4-RD). We present two of the first cases of iMCD-IPL diagnosed in British Columbia, Canada. Both patients had normolipemic bilateral xanthelasma palpebrum, which has not previously been reported in iMCD-IPL. Case report Both patients were Asian women in the 5 th decade who presented with anemia, inflammation, polyclonal hypergammaglobulinemia (PHGG), and xanthelasmas. IgG4-RD was initially suspected, but upon review of the lymph node histology and careful clinicopathological correlation, both were found to have iMCD-IPL with plasmacytic histology. Biopsies of the xanthelasmas revealed foamy macrophages consistent with common xanthelasmas. Both patients had partial clinical and biochemical response to siltuximab, but no change in xanthelasmas. We searched the literature and identified three cases of unicentric Castleman’s disease (UCD) with xanthomas, systemic inflammation and PHGG. These three patients showed marked improvement in both systemic symptoms and xanthomas after resection of the UCD. Conclusion We report two patients with normolipemic xanthelasmas and iMCD-IPL whose xanthelasmas did not regress with siltuximab. However, the regression of xanthomas in three cases of UCD from the literature suggest a potential pathophysiological association between Castleman disease and xanthomas.

Fields of Study & Subjects

Viral-associated cancers and disorders IgG4-Related and Inflammatory Diseases Histiocytic Disorders and Treatments

Publication details

Journal / source
Frontiers in Hematology
Publisher
Frontiers Media SA
Volume
5
Publication date
23 February 2026